Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models
- PMID: 19399874
- PMCID: PMC2910719
- DOI: 10.1002/ana.21603
Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models
Abstract
Objective: Conventional anticonvulsants reduce neuronal excitability through effects on ion channels and synaptic function. Anticonvulsant mechanisms of the ketogenic diet remain incompletely understood. Because carbohydrates are restricted in patients on the ketogenic diet, we evaluated the effects of limiting carbohydrate availability by reducing glycolysis using the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in experimental models of seizures and epilepsy.
Methods: Acute anticonvulsant actions of 2DG were assessed in vitro in rat hippocampal slices perfused with 7.5mM [K(+)](o), 4-aminopyridine, or bicuculline, and in vivo against seizures evoked by 6 Hz stimulation in mice, audiogenic stimulation in Fring's mice, and maximal electroshock and subcutaneous pentylenetetrazol (Metrazol) in rats. Chronic antiepileptic effects of 2DG were evaluated in rats kindled from olfactory bulb or perforant path.
Results: 2DG (10mM) reduced interictal epileptiform bursts induced by 7.5mM [K(+)](o), 4-aminopyridine, and bicuculline, and electrographic seizures induced by high [K(+)](o) in CA3 of hippocampus. 2DG reduced seizures evoked by 6 Hz stimulation in mice (effective dose [ED]50 = 79.7 mg/kg) and audiogenic stimulation in Fring's mice (ED50 = 206.4 mg/kg). 2DG exerted chronic antiepileptic action by increasing afterdischarge thresholds in perforant path (but not olfactory bulb) kindling and caused a twofold slowing in progression of kindled seizures at both stimulation sites. 2DG did not protect against maximal electroshock or Metrazol seizures.
Interpretation: The glycolytic inhibitor 2DG exerts acute anticonvulsant and chronic antiepileptic actions, and has a novel pattern of effectiveness in preclinical screening models. These results identify metabolic regulation as a potential therapeutic target for seizure suppression and modification of epileptogenesis.
Figures
Similar articles
-
Seizure suppression via glycolysis inhibition with 2-deoxy-D-glucose (2DG).Epilepsia. 2008 Nov;49 Suppl 8:97-100. doi: 10.1111/j.1528-1167.2008.01848.x. Epilepsia. 2008. PMID: 19049601 Review.
-
Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.Epilepsia. 2001 Jul;42(7):831-6. doi: 10.1046/j.1528-1157.2001.042007831.x. Epilepsia. 2001. PMID: 11488880
-
2-Deoxy-d-glucose reduces epileptiform activity by presynaptic mechanisms.J Neurophysiol. 2019 Apr 1;121(4):1092-1101. doi: 10.1152/jn.00723.2018. Epub 2019 Jan 23. J Neurophysiol. 2019. PMID: 30673364
-
2-Deoxy-D-glucose administration after seizures has disease-modifying effects on kindling progression.Epilepsy Res. 2023 Jul;193:107169. doi: 10.1016/j.eplepsyres.2023.107169. Epub 2023 May 24. Epilepsy Res. 2023. PMID: 37263021
-
The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?Neurochem Res. 2017 Jul;42(7):1926-1938. doi: 10.1007/s11064-016-2025-7. Epub 2016 Aug 8. Neurochem Res. 2017. PMID: 27502939 Review.
Cited by
-
Mitochondrial involvement and oxidative stress in temporal lobe epilepsy.Free Radic Biol Med. 2013 Sep;62:121-131. doi: 10.1016/j.freeradbiomed.2013.02.002. Epub 2013 Feb 11. Free Radic Biol Med. 2013. PMID: 23411150 Free PMC article. Review.
-
Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.P T. 2010 Jul;35(7):392-415. P T. 2010. PMID: 20689626 Free PMC article. No abstract available.
-
Glycolytic inhibition by 2-deoxy-d-glucose abolishes both neuronal and network bursts in an in vitro seizure model.J Neurophysiol. 2017 Jul 1;118(1):103-113. doi: 10.1152/jn.00100.2017. Epub 2017 Apr 12. J Neurophysiol. 2017. PMID: 28404824 Free PMC article.
-
Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation.Neurochem Res. 2021 Aug;46(8):1895-1912. doi: 10.1007/s11064-021-03332-y. Epub 2021 Apr 30. Neurochem Res. 2021. PMID: 33929683 Free PMC article. Review.
-
Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.Exp Neurol. 2023 Feb;360:114288. doi: 10.1016/j.expneurol.2022.114288. Epub 2022 Nov 26. Exp Neurol. 2023. PMID: 36471511 Free PMC article. Review.
References
-
- Vining EPG. Clinical efficacy of the ketogenic diet. Epilepsy Res. 1999;37:181–190. - PubMed
-
- Stafstrom CE, Bough KJ. The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci. 2003;6:67–79. - PubMed
-
- Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. 2007;48:43–58. - PubMed
-
- Huttenlocher PR. Ketonemia and seizures: Metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res. 1976;10:536–540. - PubMed
-
- Sutula TP, Ockuly J, Stafstrom CE, Roopra A. Novel anticonvulsant, antiepileptic properties and favorable toxicology profile of 2-deoxy-D-glucose (2DG) in experimental models of epilepsy. Epilepsia. 2006
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
